Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery

Inclusion Criteria: * Documented informed consent of the participant and/or legally authorized representative * Eastern Cooperative Oncology Group performance status 0-2 * Life expectancy \> 3 months * Intrahepatic cholangiocarcinoma; a histological diagnosis is mandated; a diagnosis of adenocarcinoma with staining pattern consistent with cholangiocarcinoma and with a clinical presentation consistent with cholangiocarcinoma will be acceptable for enrollment as this is a typical intrahepatic cholangiocarcinoma presentation * Primary tumor deemed unresectable by hepatobiliary surgeon * Absence of the following: * Malignant ascites * Extensive carcinomatosis (in the opinion of the investigator) * Bulky, diffuse adenopathy (\> 5 lymph nodes \> 2 cm each) * Extensive metastatic disease to the lungs (\> 5 tumors \> 2 cm each) * Has completed pre-RE angiogram up to 3 weeks prior to Y-90 therapy * Lung shunt fraction =\< 20% and anatomy amenable to intra-arterial radiation delivery * Extrahepatic vessels deemed at risk for radiation injury were successfully embolized * Prior systemic chemotherapy must be completed \> 2 weeks of radioembolization * Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient of childbearing potential only) * Platelets (PLT) \>= 100,000/mm\^3 * Absolute neutrophil count (ANC) \>= 1500 cells/mm\^3 * Creatinine clearance of \> 50 mL/min per 24 hour urine collection of the Cockcroft-Gault formula * Hemoglobin \> 9 g/…